Use of a vinorelbine compound (4-(acetyloxy)-6,7-didehydro-15-((2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino(4,3-b)indol-8-yl)-3-hydroxy-16-methoxy-1-methyl- methyl ester, (2beta, 3beta, 4beta, 5alpha, 12R, 19alpha)-aspidospermidine-3-carboxylic acid) and a HKI-272 ((E)-N-{ 4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyI} -4-(dimethylamino)-2-butenamide) compound in the manufacture of a medicament for treating a neoplasm in a subject, wherein said neoplasm is selected from the group consisting of a lung cancer, breast cancer, myeloma, prostate cancer, head and neck cancer, transitional cell carcinoma, small cell neuroendocrine carcinoma of the uterine cervix, and large cell neuroendocrine carcinoma of the uterine cervix.
